| Clinical data | |
|---|---|
| Trade names | Eylea |
| Licence data | US FDA:link |
| Pregnancy cat. | C(US) |
| Legal status | ℞-only (US) |
| Routes | Injection |
| Identifiers | |
| CAS number | 862111-32-8 |
| ATC code | S01LA05 |
| UNII | 15C2VL427D |
| KEGG | D09574 |
| Chemical data | |
| Formula | C4318H6788N1164O1304S32 |
| Mol. mass | 96.90 kDa |
| (what is this?) (verify) |
|
Aflibercept is a fusion protein approved in the United States for the treatment of wet macular degeneration. It is under development for the treatment of cancer.
It is an inhibitor of vascular endothelial growth factor.[1][2] It is designed to bind to VEGF-A, VEGF-B, and placental growth factor (PIGF).[3]
Aflibercept is being co-developed by Sanofi-Aventis and Regeneron Pharmaceuticals.
In November 2011 the United States Food and Drug Administration approved aflibercept for the treatment of wet macular degeneration.[4]
In March 2011 Regeneron reported that aflibercept failed its primary endpoint of overall survival in the Vital phase III trial for second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), although it improved the secondary endpoint of progression-free survival.[5][3]
In April 2011 Regeneron reported that aflibercept improved its primary endpoint of overall survival in the Velour phase III clinical trial for second-line treatment for metastatic colorectal cancer (mCRC).[3]
Aflibercept is also in a phase III trial for hormone-refractory metastatic prostate cancer.[3]
|
||||||||||||||
|
|||||||||||||||||||||||||||||